Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | PSEN1 | P49768 | 9/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 6/20 | 0.35 |
| ▸ | ACHE | P22303 | 6/20 | 0.35 |
| ▸ | TTPA | P49638 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23961349 | 0.88 | PTGS1 (0.48) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL7453293 | 0.87 | PTGS1 (0.47) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL20819462 | 0.84 | PTGS1 (0.45) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL10071787 | 0.84 | PTGS1 (0.45) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL15150900 | 0.82 | PSEN1 (0.47) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL11705987 | 0.82 | PTGS1 (0.41) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL13933085 | 0.81 | PTGS1 (0.79) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL4278692 | 0.79 | PTGS1 (0.63) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL5460830 | 0.79 | PTGS1 (0.36) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL29242853 | 0.79 | PSEN1 (0.53) | PTGS1PTGS2CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962246-B2 | Method for providing DNA fragments derived from an archived sample | EPIGENOMICS AG (DE) | 2015-02-24 | — | — | US | claimed |
| EP-1869215-B1 | IMPROVED BISULFITE CONVERSION OF DNA | EPIGENOMICS AG (DE) | 2014-05-07 | — | — | EP | claimed |
| US-20140087449-A1 | Method for Providing DNA Fragments Derived from an Archived Sample | EPIGENOMICS AG (DE) | 2014-03-27 | — | — | US | claimed |
| US-20040053993-A1 | Compositions of tocol-soluble therapeutics | SONUS PHARMACEUTICALS, INC. | 2004-03-18 | — | — | US | claimed |
| US-6479540-B1 | Compositions of tocol-soluble therapeutics | SONUS PHARMACEUTICALS, INC. | 2002-11-12 | — | — | US | claimed |
| EP-1216026-A1 | COMPOSITIONS OF TOCOL-SOLUBLE THERAPEUTICS | SONUS PHARMACEUTICALS, INC. (US) | 2002-06-26 | — | — | EP | claimed |
| WO-2001022937-A1 | COMPOSITIONS OF TOCOL-SOLUBLE THERAPEUTICS | SONUS PHARMACEUTICALS, INC. (US) | 2001-04-05 | — | — | WO | claimed |
| WO-2023066775-A1 | SUPRAPARTICLE AND ADDITIVE FOR OPTICALLY INDICATING HYDROGEN GAS, METHOD FOR PRODUCING THE SUPRAPARTICLE(S) OR THE ADDITIVE, AND USE OF THE SUPRAPARTICLE(S) OR THE ADDITIVE | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2023-04-27 | — | — | WO | disclosed |
| WO-2021141926-A1 | METHOD, AND SYSTEM FOR MULTI-LAYER COSMETIC PADS AND USE THEREOF | ELC MANAGEMENT LLC (US) | 2021-07-15 | — | — | WO | disclosed |
| CN-107638316-A | Purposes and skin care item of the Cordyceps sinensis fungus products of cellular metabolism in skin care item are prepared | 徐跃 | 2018-01-30 | — | — | CN | disclosed |
| EP-2838899-B1 | THIAZOLIDINEDIONE DERIVATIVES, THEIR PREPARATION AND USE IN THE TREATMENT OF CANCERS | UNIV LORRAINE (FR) | 2016-10-05 | — | — | EP | disclosed |
| EP-2838899-A1 | THIAZOLIDINEDIONE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN CANCER TREATMENT | Université de Lorraine (FR) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013110796-A1 | THIAZOLIDINEDIONE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN CANCER TREATMENT | UNIVERSITÉ DE LORRAINE (FR) | 2013-08-01 | — | — | WO | disclosed |
| WO-2002076938-A2 | CARBOXYBENZOPYRAN DERIVATIVES AND COMPOSITIONS | SONUS PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6413962-B1 | ANESTHESIA AND TEMPERATURES REDUCTION; ALPHA-ADRENOCEPTOR AGONIST; RESTORATIVE TO CENTRAL NERVOUS SYSTEM, ESPECIALLY MOTOR AND SENSORY FUNCTIONAL LOSSES FROM TRAMATIC SPINAL CORD INJURIES; ANTISPASTICS; NONSEDATIVE; SIDE EFFECT REDUCTION | NAFTCHI N ERIC (US) | 2002-07-02 | — | — | US | disclosed |
| EP-1216026-A1 | COMPOSITIONS OF TOCOL-SOLUBLE THERAPEUTICS | SONUS PHARMACEUTICALS, INC. (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2002026208-A2 | EMULSION VEHICLE FOR POORLY SOLUBLE DRUGS | SONUS PHARMACEUTICALS, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
| WO-2002026324-A2 | TOCOL-BASED COMPOSITIONS CONTAINING AMIODARONE | SONUS PHARMACEUTICALS, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
| WO-2001022937-A1 | COMPOSITIONS OF TOCOL-SOLUBLE THERAPEUTICS | SONUS PHARMACEUTICALS, INC. (US) | 2001-04-05 | — | — | WO | disclosed |
| EP-0398132-A2 | Phosphorous compounds | F. HOFFMANN-LA ROCHE AG (CH) | 1990-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053993-A1 | Compositions of tocol-soluble therapeutics | TTPA, SLC25A13, PCTP | PTGS1 863/4885PTGS2 820/4885CYP1A2 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.